Researchers utilize a modified self-controlled case-series study to assess the risks of thromboembolism after COVID-19 vaccination SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Development of coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the current endemic status of COVID-19, patients with comorbidities and older adults remain vulnerable to severe illness and death due to CO

FORT WORTH, Texas, Nov. 15, 2024 /PRNewswire/ -- VERTESS (), a leading healthcare mergers and acquisitions (M&A) advisory firm, is pleased to announce that Momentum (), a Maine behavioral health provider that offers shared living and other services to people with intellectual and development disabilities, has joined the Mosaic () family. Momentum is now part of Living Innovations (), a service of Mosaic. Together they have increased their reach to people with diverse needs in Maine, New Hamp

OBODENCE™ and XBRYK™ recommended for approval by the European Medicines Agency for all indications referencing Prolia and Xgeva, respectivelyINCHEON, South Korea, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for two denosumab biosimilars – OBODENCE™ (60 mg pre-filled syringe) referencing Prolia (denosumab) and XBRYK™ (120mg vial) referen

DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE™ to a third hospital customer. QUELIMMUNE is the Company’s Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis. “Within weeks of implement

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference Format:Pre

PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC). Of significance, the CheckMate -8HW trial results showe

AUSTIN, Texas, Nov. 15, 2024 /PRNewswire/ -- Today, Mindbloom, the largest provider of psychedelic therapy, and Happier, the leading meditation and habit-building app, announce Continuous Transformation – a partnership to enable people to deepen their mindfulness practices and unlock emotional healing. Continue Reading Mindbloom and Happier Break New Ground with the Ultimate Fusion of Ketamine Therapy and Mindfulness "As a dedicated meditator for over a decade, I've experienced the profound syn

NEW ORLEANS--( BUSINESS WIRE )--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem cell (iPSC) and bio data repository. The repository encompasses biological and clinical data from nearly 1,000 ALS patients, offering an unprecedented resource for global researchers studying ALS, commonly known as Lou Gehrig's disease. Led by Dhruv Sareen, Ph.D., Exe

Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecu

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pego